|
In Vitro Metabolism Study of NDSRIs
|
|
3
|
332
|
November 20, 2025
|
|
Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018–2025)-Pub
|
|
0
|
244
|
November 18, 2025
|
|
N nitroso urapidil
|
|
0
|
94
|
November 18, 2025
|
|
Nitrosamine Control: From Risk Assessment to Analytical Testing with Emphasis on Sample Preparation and Phase-Appropriate Method Validation-Pub
|
|
0
|
356
|
November 8, 2025
|
|
Peptide Synthesis - Does anyone have experience with potential Nitrosamine impurities coming from solid phase synthesis?
|
|
1
|
210
|
October 16, 2025
|
|
Sample Prep for Complex Matrices - creams etc?
|
|
1
|
189
|
October 10, 2025
|
|
Monitoring the Concentration of Nitrogen Oxides in the Fluidized Bed Drying/Granulation Process and Evaluation of Reduction Methods
|
|
2
|
566
|
September 28, 2025
|
|
A Simple and Scalable Synthesis of N-Nitroso Salbutamol Impurities A, D, and F -Pub
|
|
1
|
201
|
September 27, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
5325
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
422
|
September 4, 2025
|
|
N-nitrosamines: in silico modelling of DNA reactivity and identification of metabolic precursors
|
|
0
|
171
|
August 12, 2025
|
|
Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling
|
|
1
|
167
|
August 7, 2025
|
|
Nitrosamine Formation with Lidocaine in Ointments and Injections
|
|
1
|
482
|
August 5, 2025
|
|
Synthesis of Nitroso Derivatives of Dihydropyridine Calcium Channel Blockers
|
|
5
|
777
|
July 31, 2025
|
|
Alignment between Duplex Sequencing and transgenic rodent mutation assay data in the assessment of in vivo NDMA-induced mutagenesis-Pub
|
|
0
|
148
|
July 21, 2025
|
|
Can anybody have scientific rationale about the non formation of N-nitroso-amlodipine
|
|
3
|
725
|
July 18, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
277
|
July 12, 2025
|
|
Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease -Pub
|
|
0
|
145
|
June 25, 2025
|
|
N-Nitroso Phenylephrine and N-Nitroso Phenylephrone
|
|
1
|
316
|
June 25, 2025
|
|
Mitigation of N-Nitrosamine Formation in Ranitidine Hydrochloride by Spray Drying Co-Precipitation with Mannitol, Dextrin, and Antioxidant-Pub
|
|
0
|
153
|
June 21, 2025
|
|
Atmospheric Formation of Nitrosamines in Seoul, Korea
|
|
0
|
242
|
June 9, 2025
|
|
New Paper: Impact of antioxidant addition on drug dissolution: Implications for NDSRI mitigation biowaivers
|
|
1
|
322
|
June 5, 2025
|
|
Comparative DNA damage induced by 8 nitrosamines in primary human and macaque hepatocytes -Pub
|
|
1
|
157
|
May 27, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
33
|
2815
|
May 27, 2025
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
854
|
May 23, 2025
|
|
Metformin and nitrosation of guanidines
|
|
8
|
579
|
May 21, 2025
|
|
Using the relative potency comparison approach, Powley et al have demonstrated the safety of NTTP exposures at or above levels of 1500 ng/day
|
|
2
|
397
|
May 17, 2025
|
|
Nitrate and nitrite food composition database: an update and extensive deep dive
|
|
2
|
391
|
May 14, 2025
|
|
HESI GTTC ring trial: Concordance between Ames and rodent carcinogenicity outcomes for N-nitrosamines (NAs) with rat and hamster metabolic conditions -Pub
|
|
0
|
133
|
May 13, 2025
|
|
NitrosAMIDES - Should they be treated the same as Nitrosamines?
|
|
3
|
1028
|
May 7, 2025
|